Market Overview:
The global frontotemporal disorders treatment market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of frontotemporal disorders, rising awareness about these disorders, and advancements in treatment options. The global frontotemporal disorders treatment market is segmented on the basis of type into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and others. The cognitive enhancers segment is expected to grow at the highest CAGR during the forecast period owing to increasing research on novel drugs for treating these disorders. On the basis of application, the global frontotemporal disorder treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Product Definition:
Frontotemporal disorders treatment is the process of seeking help for and managing conditions that affect the frontal lobe and temporal lobes of the brain. These areas are responsible for aspects of personality, behavior, language, and memory. Treatment may involve medication, therapy, or a combination of both. It is important to seek treatment for these disorders because they can cause changes in mood, behavior, and cognition that can lead to difficulties in functioning socially and professionally.
Cognitive Enhancers:
Cognitive enhancers are drugs, natural supplements or devices that enhance the ability of the brain to process information. They work by improving memory, attention span and other cognitive functions. Some of them also prevent age-related mental decline.
Antipsychotics:
Antipsychotics are a class of medication primarily used to treat schizophrenia and certain forms of bipolar disorder. They work by decreasing the activity in the brain that causes symptoms such as hallucinations, paranoia, inability to execute normal motor functions and thinking etc.
Application Insights:
The other application segment includes surgical treatment, which accounted for the largest share in 2016. The growing prevalence of frontotemporal lobar encephalopathy (FLE) and its association with antipsychotics is driving the need for alternative treatment options. Frontotemporal lobar encephalopathy mainly affects elderly people and is associated with a high mortality rate. Therefore, hospital pharmacies are adopting various strategies such as distribution channels through medical stores to reach remote areas where healthcare facilities are not available or affordable, thereby contributing to market growth in this segment.
On the other hand, online pharmacies have gained popularity due to their convenience and accessibility coupled with cost-effectiveness compared to retail pharmacies or hospital pharmacies.
Regional Analysis:
North America accounted for the largest share of global revenue in 2017. The region is expected to maintain its dominance during the forecast period owing to increasing prevalence of frontotemporal lobar degeneration and rising healthcare expenditure. Moreover, availability of well-established healthcare facilities and high adoption rate of novel drugs are also driving growth in this region.
Asia Pacific is estimated to be the fastest growing regional market from 2018 to 2030 due to improving economic conditions, increasing disposable income levels, coupled with a rise in consumer awareness regarding various treatment options available forfrontotemporal disorders patients. In addition, increase in number of neurology outpatient departments & hospitals as well as neurological centers will boost demand over the forecast period. Furthermore, increase in incidence rates associated with lifestyle factors such as smoking and alcohol consumption will drive growth further on account of an increased demand for antidepressants and antipsychotics among these groups respectively (Singh et al., 2016).
Growth Factors:
- Increasing awareness about frontotemporal disorders and its treatment options among people.
- Growing number of research studies on frontotemporal disorders that would help in understanding the disease better and finding new treatment methods.
- Development of novel drugs and therapies for frontotemporal disorders, which would offer better treatment options to patients.
- increasing incidence of frontotemporal disorders due to changing lifestyle and environmental factors 5 Increased focus on early diagnosis and intervention for frontotemporal disorders, which would improve the prognosis for patients
Scope Of The Report
Report Attributes
Report Details
Report Title
Frontotemporal Disorders Treatment Market Research Report
By Type
Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
GlaxoSmithKline, Pfizer, Sanofi, Eli Lilly, Merck, Johnson & Johnson, AstraZeneca, Allergan, Mylan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
138
Number of Tables & Figures
97
Customization Available
Yes, the report can be customized as per your need.
Global Frontotemporal Disorders Treatment Market Report Segments:
The global Frontotemporal Disorders Treatment market is segmented on the basis of:
Types
Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Pfizer
- Sanofi
- Eli Lilly
- Merck
- Johnson & Johnson
- AstraZeneca
- Allergan
- Mylan
Highlights of The Frontotemporal Disorders Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cognitive Enhancers
- Antipsychotics
- Antidepressants
- CNS Stimulants
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Frontotemporal Disorders Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Frontotemporal disorders treatment is a combination of medications, therapies, and support services that are aimed at improving the quality of life for people with FTD. Treatment may include medication to improve mood and behavior, therapy to help patients learn new skills or cope with changes in their lives, and support services such as home care or assistance with activities of daily living.
Some of the major companies in the frontotemporal disorders treatment market are GlaxoSmithKline, Pfizer, Sanofi, Eli Lilly, Merck, Johnson & Johnson, AstraZeneca, Allergan, Mylan.
The frontotemporal disorders treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Frontotemporal Disorders Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Frontotemporal Disorders Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Frontotemporal Disorders Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Frontotemporal Disorders Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Frontotemporal Disorders Treatment Market Size & Forecast, 2020-2028
4.5.1 Frontotemporal Disorders Treatment Market Size and Y-o-Y Growth
4.5.2 Frontotemporal Disorders Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Cognitive Enhancers
5.2.2 Antipsychotics
5.2.3 Antidepressants
5.2.4 CNS Stimulants
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Frontotemporal Disorders Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Frontotemporal Disorders Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Cognitive Enhancers
9.6.2 Antipsychotics
9.6.3 Antidepressants
9.6.4 CNS Stimulants
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Cognitive Enhancers
10.6.2 Antipsychotics
10.6.3 Antidepressants
10.6.4 CNS Stimulants
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Cognitive Enhancers
11.6.2 Antipsychotics
11.6.3 Antidepressants
11.6.4 CNS Stimulants
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Cognitive Enhancers
12.6.2 Antipsychotics
12.6.3 Antidepressants
12.6.4 CNS Stimulants
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Cognitive Enhancers
13.6.2 Antipsychotics
13.6.3 Antidepressants
13.6.4 CNS Stimulants
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Frontotemporal Disorders Treatment Market: Competitive Dashboard
14.2 Global Frontotemporal Disorders Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 Pfizer
14.3.3 Sanofi
14.3.4 Eli Lilly
14.3.5 Merck
14.3.6 Johnson & Johnson
14.3.7 AstraZeneca
14.3.8 Allergan
14.3.9 Mylan
